The continuing advancement of next-generation technology in terms of data capacity per instrument run and read length is likely to accelerate the rate of whole genome sequencing, at ever-decreasing costs. Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a group of tumor cells. The cancer genome engineering market is growing rapidly due to the technological advancements, government initiatives, R&D funding in the genome sequencing sector and higher incidence of cancer worldwide. The next-generation platforms can produce data to characterize gene expression, methylation, histone packaging, transcription factor and other regulatory protein binding positions, where it is quite possible to comprehensively characterize a broad spectrum of genomic alterations among sets of tumor samples.
The global cancer genome sequencing market report estimates the market size (Revenue US$ million – 2014 to 2021) and composition of this market in terms of technology types (second and third generation sequencing), cancer types (breast cancer, prostate cancer, colorectal cancer, etc.) and forecasts growth trends (CAGR% – 2017 to 2021).
The global cancer genome sequencing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global cancer genome sequencing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global cancer genome sequencing market and included in this report are Pacific Biosciences of California, Inc., GE Healthcare, Beckman Genomics, Genewiz, Inc. Foundation Medicine, Inc. Myriad Genetics, Illumina, Inc. Thermo Fisher Scientific, Inc., and F. Hoffman la Roche AG.